background
palivizumab
human
monoclon
antibodi
prevent
sever
human
respiratori
syncyti
viru
hrsv
infect
object
determin
etiolog
respiratori
viral
infect
palivizumab
recipi
monitor
clinic
outcom
hrsv
genotyp
hrsvinfect
infant
studi
design
nasopharyng
aspir
npa
collect
children
receiv
palivizumab
consult
hospit
acut
respiratori
tract
infect
arti
season
viral
cultur
multiplex
rtpcr
influenza
ab
hrsv
human
metapneumoviru
perform
fusion
f
gene
hrsv
amplicon
also
sequenc
result
among
enrol
patient
episod
arti
total
visit
least
one
viru
identifi
npa
sampl
hrsv
account
confirm
viral
etiolog
compar
subject
viral
arti
hrsvposit
subject
less
fever
p
tend
bronchiol
p
ten
subject
visit
develop
hrsv
infect
although
one
hospit
hrsv
detect
median
palivizumab
dose
median
day
last
dose
one
hrsv
strain
test
f
mutat
locat
palivizumabbind
site
conclus
hrsv
still
major
caus
arti
children
receiv
palivizumab
although
outcom
infect
children
appear
mild
human
respiratori
syncyti
viru
hrsv
major
caus
lower
respiratori
tract
infect
prematur
babi
infant
less
month
old
elderli
institution
subject
greenough
welliv
although
hrsvinfect
infant
requir
hospit
infect
associ
hospit
attribut
bronchiol
hospit
attribut
pneumonia
ogra
us
estim
hrsv
infect
account
approxim
hospit
death
yearli
ogra
thompson
et
al
palivizumab
synagi
medimmun
inc
gaithersburg
md
human
monoclon
antibodi
direct
hrsv
fusion
f
glycoprotein
johnson
et
al
meissner
palivizumab
recommend
hrsv
season
prematur
babi
week
gestat
subset
week
infant
year
age
chronic
lung
problem
congenit
heart
diseas
felt
et
al
impactrsv
studi
group
despit
increas
use
palivizumab
pauciti
data
regard
impact
immunoprophylaxi
viral
etiolog
acut
respiratori
tract
infect
arti
treat
infant
purpos
studi
determin
viral
etiolog
upper
lower
respiratori
tract
infect
palivizumab
recipi
monitor
clinic
outcom
viral
f
protein
genotyp
hrsvinfect
infant
parent
infant
receiv
least
dose
palivizumab
hrsv
season
larg
privat
pediatr
clinic
citi
qc
canada
invit
particip
inform
consent
obtain
elig
particip
patient
live
remot
area
enrol
demograph
medic
questionnair
complet
parent
advis
contact
research
nurs
whenev
child
experienc
respiratori
tract
infect
without
fever
sever
enough
warrant
medic
evalu
contact
research
nurs
schedul
medic
appoint
day
clinic
week
day
told
parent
consult
emerg
room
citi
pediatr
hospit
weekend
holiday
site
physician
instruct
collect
nasopharyng
aspir
npa
virolog
analys
fill
questionnair
clinic
symptom
addit
monthli
interv
time
palivizumab
administr
parent
ask
consult
hospit
child
studi
approv
ethic
committe
centr
hospitali
universitair
de
aliquot
l
npa
dilut
hank
medium
inocul
day
collect
panel
ten
continu
cell
line
viral
cultur
previous
describ
boivin
et
al
respiratori
virus
typic
identifi
cell
cultur
laboratori
includ
influenza
b
parainfluenza
piv
hrsv
human
metapneumoviru
hmpv
adenovirus
addit
second
aliquot
l
npa
reserv
multiplex
realtim
pcr
assay
amplifi
influenza
matrix
influenza
b
matrix
hrsv
f
protein
hmpv
nucleoprotein
gene
previous
describ
boivin
et
al
hamelin
et
al
lower
limit
detect
multiplex
assay
copi
influenza
ab
copi
hrsv
copi
hmpv
use
transcrib
plasmid
entir
f
gene
sequenc
determin
amplicon
hrsvposit
specimen
align
correspond
sequenc
strain
genbank
access
number
genotyp
virus
strain
genbank
access
number
genotyp
b
virus
proport
compar
use
fisher
exact
test
mean
compar
use
kruskalw
test
test
statist
signific
twotail
signific
set
level
sa
institut
softwar
version
use
data
statist
analysi
total
infant
receiv
least
dose
palivizumab
recruit
studi
tabl
mean
age
birth
week
indic
palivizumab
prematur
week
prematur
week
risk
factor
pulmonari
condit
cardiac
condit
condit
seven
prematur
children
also
cardiopulmonari
condit
total
subject
least
one
underli
diseas
receiv
chronic
oxygen
therapi
begin
studi
mean
age
first
dose
palivizumab
month
mean
number
dose
palivizumab
receiv
per
particip
hrsv
season
rang
interv
day
palivizumab
inject
occur
patient
first
second
dose
patient
second
third
dose
patient
third
fourth
dose
patient
fourth
fifth
dose
patient
fifth
sixth
dose
patient
sixth
seventh
dose
patient
seventh
eighth
dose
among
patient
enrol
studi
consult
arti
total
visit
outpati
consult
hospit
mean
visitssubject
due
three
miss
questionnair
visit
subject
analyz
meanmedian
age
time
visit
month
month
outpati
inpati
respect
p
mean
number
day
onset
symptom
collect
npa
rang
day
npa
collect
within
day
onset
symptom
visit
outpati
consult
hospit
frequent
clinic
diagnos
attend
physician
includ
upper
respiratori
tract
infect
urti
visit
outpati
consult
hospit
bronchiol
defin
clinic
visit
outpati
consult
hospit
pneumon
defin
new
infiltr
chest
xray
visit
outpati
consult
hospit
p
diagnos
report
includ
otiti
media
pharyng
croup
flulik
ill
least
one
viru
identifi
viral
cultur
andor
multiplex
realtim
rtpcr
npa
specimen
collect
among
virus
identifi
hrsv
rtpcr
cultur
piv
cultur
hmpv
rtpcr
cultur
adenovirus
cultur
influenza
rtpcr
cultur
influenza
b
rtpcr
cultur
coinfect
hmpv
adenoviru
combin
rtpcr
cultur
due
small
number
subject
confirm
viral
etiolog
three
group
consid
analysi
hrsvposit
virusposit
virusneg
patient
tabl
mean
age
time
npa
month
three
group
respect
p
mean
interv
onset
symptom
collect
npa
day
three
group
respect
p
similar
three
group
visit
consid
signific
differ
group
presenc
cough
p
wheez
p
hrsvposit
children
significantli
less
fever
p
children
two
group
compar
children
viral
infect
hrsvinfect
subject
bronchiol
vs
p
less
urti
vs
p
three
palivizumabtr
children
confirm
pneumon
one
posit
hmpv
two
viru
detect
among
hospit
children
one
hrsv
hmpv
adenoviru
influenza
b
infect
viral
etiolog
total
npa
posit
hrsv
children
subject
two
posit
npa
consecut
visit
day
apart
tabl
thu
recruit
infant
palivizumab
consult
hospit
arti
posit
hrsv
hrsv
infect
occur
throughout
studi
period
case
end
januari
end
april
comparison
peak
hrsv
activ
provinc
quebec
year
extend
begin
februari
midmarch
data
shown
seven
hrsvposit
subject
receiv
palivizumab
prematur
week
gestat
wherea
three
born
week
gestat
risk
factor
mean
age
ten
hrsvposit
subject
time
first
npa
collect
month
median
rang
month
children
receiv
mean
dose
palivizumab
median
rang
mean
interv
time
last
dose
palivizumab
detect
hrsv
day
median
rang
day
seven
hrsvposit
subject
diagnosi
bronchiol
although
one
hospit
period
day
tabl
child
develop
bronchiol
necessit
supplement
oxygen
day
fourth
palivizumab
inject
genotyp
hrsv
strain
subject
reveal
presenc
group
b
group
strain
sequenc
analysi
hrsv
f
protein
gene
amplifi
directli
clinic
specimen
except
strain
amplifi
viral
isol
reveal
presenc
nonsil
mutat
tabl
notabl
hrsv
b
strain
patient
contain
amino
acid
chang
codon
ke
part
known
bind
epitop
palivizumab
zhao
et
al
child
receiv
highest
number
palivizumab
dose
noncompl
bronchiol
necessit
hospit
approxim
children
receiv
palivizumab
prophylaxi
cohort
studi
experienc
hrsv
infect
sever
enough
parent
seek
medic
attent
season
although
hrsvposit
children
diagnosi
bronchiol
case
mild
one
child
requir
hospit
hrsv
infect
occur
signific
number
dose
palivizumab
median
dose
rel
shortli
dose
median
day
case
hrsv
infect
could
explain
emerg
resist
palivizumab
possibl
except
one
child
palivizumab
human
neutral
immunoglobulin
monoclon
antibodi
direct
f
protein
hrsv
approv
prevent
sever
hrsv
infect
highrisk
children
impactrsv
studi
group
cotton
rat
studi
show
mean
serum
level
palivizumab
gml
result
reduct
hrsv
titer
lung
johnson
et
al
johnson
et
al
protect
effect
palivizumab
confirm
larg
multicent
clinic
trial
highrisk
children
receiv
monthli
antibodi
administr
studi
demonstr
reduct
hrsvrelat
hospit
impactrsv
studi
group
protect
effect
palivizumab
also
confirm
subgroup
young
children
hemodynam
signific
congenit
heart
diseas
felt
et
al
systemat
assess
viral
etiolog
clinic
outcom
associ
upper
lower
respiratori
tract
infect
sever
enough
warrant
medic
consult
highrisk
patient
receiv
palivizumab
winter
season
approxim
children
born
prematur
week
gestat
underli
diseas
mean
number
palivizumab
dose
receiv
per
child
tabl
characterist
receiv
dose
highlight
extend
hrsv
period
commun
studi
despit
palivizumab
prophylaxi
hrsv
frequent
detect
viru
account
arti
confirm
viral
etiolog
hrsvinfect
children
significantli
less
fever
subject
viral
infect
signific
differ
rate
wheez
virus
hmpv
rhinovirus
associ
wheez
episod
exacerb
asthma
jartti
et
al
william
et
al
also
hrsvinfect
children
frequent
diagnos
bronchiol
subject
viral
infect
p
less
frequent
episod
urti
p
thu
bronchiol
complet
prevent
children
receiv
palivizumab
howev
among
children
confirm
hrsv
bronchiol
one
youngest
child
requir
hospit
none
pneumon
overal
data
confirm
result
previou
placebocontrol
trial
show
main
effect
palivizumab
reduc
hospit
patient
hrsv
infect
impactrsv
studi
group
unexpect
result
studi
time
hrsv
infect
palivizumabtr
children
shown
tabl
hrsv
infect
occur
minimum
dose
palivizumab
median
median
day
last
dose
breakthrough
infect
could
explain
intens
viral
circul
commun
sinc
occur
throughout
studi
period
previou
studi
shown
mean
trough
serum
antibodi
concentr
increas
number
palivizumab
dose
reach
gml
fourth
dose
impactrsv
studi
group
level
serum
neutral
antibodi
titer
good
correl
protect
hrsv
piedra
et
al
explan
occurr
hrsv
infect
may
inadequ
antibodi
level
present
children
altern
palivizumab
could
lost
neutral
activ
due
emerg
specif
viral
mutat
factor
specif
cellmedi
immun
may
involv
protect
hrsv
infect
vitro
anim
studi
select
palivizumabresist
hrsv
escap
mutant
reveal
critic
region
encompass
amino
acid
f
protein
beeler
van
wyke
coelingh
zhao
et
al
b
zhao
sullend
particular
mutat
codon
ly
met
gln
codon
asn
ile
associ
complet
partial
vitro
resist
respect
palivizumab
note
mutant
associ
resist
infus
antibodi
cotton
rat
zhao
et
al
b
zhao
sullend
date
report
palivizumabresist
hrsv
strain
children
although
limit
number
virus
infant
receiv
prophylaxi
evalu
devincenzo
et
al
johnson
et
al
f
protein
amino
acid
chang
found
studi
one
ly
glu
locat
put
drugbind
site
could
potenti
confer
resist
palivizumab
mutant
viru
select
dose
palivizumab
grow
initi
cell
cultur
rtpcr
posit
furthermor
infect
child
unev
bronchiol
fact
could
suggest
mutant
viru
decreas
viral
fit
antibodi
still
partial
effect
addit
work
also
requir
evalu
potenti
new
human
monoclon
antibodi
deriv
palivizumab
motavizumab
medimmun
inc
increas
bind
affin
palivizumabresist
strain
mejia
et
al
relev
hrsv
f
protein
chang
detect
studi
unclear
compar
analysi
strain
hrsv
hrsv
b
f
protein
sequenc
avail
genbank
show
mutat
previous
report
one
hrsv
isol
data
shown
studi
limit
first
control
untreat
group
compar
viral
etiolog
outcom
palivizumab
recipi
howev
inclus
subject
would
uneth
time
studi
second
small
percentag
arti
confirm
viral
etiolog
probabl
reflect
absenc
specif
rtpcr
assay
detect
rhinovirus
coronavirus
human
bocaviru
also
perform
palivizumab
neutral
studi
hrsv
strain
detect
studi
lastli
elig
patient
enrol
studi
parent
give
consent
mostli
live
far
away
clinic
could
introduc
bia
result
conclus
show
hrsv
remain
major
caus
arti
children
receiv
palivizumab
prophylaxi
clinic
outcom
hrsvinfect
children
studi
gener
mild
futur
work
requir
evalu
develop
hrsv
infect
children
receiv
multipl
dose
palivizumab
determin
addit
benefit
potent
antibodi
